The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) ...

Pulmonary arterial hypertension is caused by narrowing of the blood vessels in the lungs. Learn how it happens, including ...

Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among ...

CHICAGO -- Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk ...

RAHWAY, N.J. - Merck (NYSE:MRK), a prominent player in ... mortality events in adults with pulmonary arterial hypertension (PAH), WHO functional class III or IV. The findings, presented today ...

Sotatercept, an activin signaling inhibitor, was associated with improved outcomes in patients with advanced pulmonary ...

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) functional class (FC ...